Laser and light source treatments target many of the most common skin conditions that dermatologists encounter. The recent expansion in laser dermatology is both promising and exciting as the treatments available to derms and their patients continue to grow. New technologies are taking laser and light source treatments in new directions of skin structure imaging, epidermal harvesting, tissue rejuvenation, and new types of photodynamic therapies.
Biosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars.
TNF inhibitors adalimumab and infliximab have evidence-based efficacy for the treatment of hidradentitis suppurativa (HS). Anti-interleukin inhibitors ustekinumab and anakinra also being evaluated in small studies for treatment of HS. Antibiotics, hormones, retinoids, steroids and laser therapies directly targeting the lesions round out an effective treatment plan for HS patients.